• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Cain Christopher W.

    5/1/25 5:41:29 PM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVTE alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    CAIN CHRISTOPHER W.

    (Last) (First) (Middle)
    C/O JADE BIOSCIENCES, INC.
    221 CRESCENT ST., BLDG. 23, STE. 105

    (Street)
    WALTHAM MA 02453

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    04/28/2025
    3. Issuer Name and Ticker or Trading Symbol
    Jade Biosciences, Inc. [ JBIO ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit 24 - Power of Attorney
    No securities are beneficially owned.
    /s/ Elizabeth Balta, as attorney-in-fact for Christopher W. Cain 05/01/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AVTE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVTE

    DatePrice TargetRatingAnalyst
    6/18/2024$27.00 → $2.00Outperform → In-line
    Evercore ISI
    6/18/2024Buy → Hold
    TD Cowen
    6/18/2024$35.00 → $2.00Overweight → Equal Weight
    Wells Fargo
    6/17/2024Buy → Neutral
    Guggenheim
    6/17/2024Buy → Neutral
    BTIG Research
    6/17/2024$41.00 → $3.00Outperform → Neutral
    Wedbush
    3/25/2024$21.00 → $65.00Buy
    Jefferies
    12/8/2023$35.00Equal Weight
    Wells Fargo
    More analyst ratings

    $AVTE
    SEC Filings

    See more
    • Aerovate Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Leadership Update, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant, Material Modification to Rights of Security Holders, Regulation FD Disclosure

      8-K - Jade Biosciences, Inc. (0001798749) (Filer)

      5/1/25 4:22:23 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Aerovate Therapeutics Inc.

      SCHEDULE 13D/A - Jade Biosciences, Inc. (0001798749) (Subject)

      4/30/25 4:51:40 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Aerovate Therapeutics, Inc. (0001798749) (Filer)

      4/29/25 4:05:20 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aerovate Therapeutics downgraded by Evercore ISI with a new price target

      Evercore ISI downgraded Aerovate Therapeutics from Outperform to In-line and set a new price target of $2.00 from $27.00 previously

      6/18/24 7:32:31 AM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics downgraded by TD Cowen

      TD Cowen downgraded Aerovate Therapeutics from Buy to Hold

      6/18/24 7:23:55 AM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Aerovate Therapeutics from Overweight to Equal Weight and set a new price target of $2.00 from $35.00 previously

      6/18/24 7:22:03 AM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals

      —Aerovate Board of Directors approves 1-for-35 reverse stock split— WALTHAM, Mass., April 21, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) ("Aerovate") today announced that its stockholders have approved the proposed merger (the "Merger") with Jade Biosciences, Inc. ("Jade"), along with all proposals related to the Merger. The proposals were voted upon at Aerovate's special meeting of stockholders held on April 16, 2025 (the "Special Meeting"), including a reverse stock split of Aerovate's common stock to be effected at the discretion of the Board of Directors (the "Board") within the parameters approved by Aerovate's stockholders. On April 18, 2025, the Board approved a fi

      4/21/25 8:00:00 AM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences

      Aggregate cash dividend of $69.6 million, or an estimated $2.40 per share WALTHAM, Mass., April 9, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) ("Aerovate") today announced that its Board of Directors has declared a special cash dividend (the "Cash Dividend") in connection with the previously announced merger (the "Merger") with Jade Biosciences, Inc. ("Jade") pursuant to the Agreement and Plan of Merger, dated October 30, 2024 (the "Merger Agreement"). The Cash Dividend will be an aggregate of $69.6 million, or an estimated $2.40 per share, payable in cash to the stockholders of record as of April 25, 2025. The estimated per share dividend is based on 28,985,019 shares of

      4/9/25 4:05:00 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences

      Cash dividend expected to be in the range of $67.6 – 69.6 million WALTHAM, Mass., April 7, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) ("Aerovate") today announced that, in connection with its previously announced merger (the "Merger") with Jade Biosciences, Inc. ("Jade"), it expects to declare a cash dividend to the pre-Merger Aerovate stockholders (the "Cash Dividend") in the range of $67.6 – 69.6 million in the aggregate. This expected dividend range is based on Aerovate's estimated net cash immediately prior to the closing of the Merger (the "Closing"). As of April 4, 2025, 28,985,019 shares of Aerovate's common stock are outstanding. Official declaration of the Cash D

      4/7/25 8:30:00 AM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ra Capital Management, L.P. bought $1,549,944 worth of shares (928,110 units at $1.67) (SEC Form 4)

      4 - Aerovate Therapeutics, Inc. (0001798749) (Issuer)

      6/20/24 5:56:07 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care